EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus

Basma Eid Abdullah Ghorab, Tongtan Liu iD, Min Ying, Ping Wang, Meirong Qin, Jiayong Xing, Huadong Wang iD, Fuqiang Xu

Viruses · 2025

DOI: 10.3390/v17040581 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Basma Eid Abdullah Ghorab und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Viral Vectors for Biomedicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, …. Hauptthemen laut MEDLINE: Oncolytic Viruses, Oncolytic Virotherapy, Simplexvirus, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Shenzhen Science and Technology Program, National Science and Technology Innovation 2030.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic herpes simplex virus (oHSV) represents a promising therapeutic approach to treating cancers by virtue of its selective replication in and lysis of tumor cells, with stimulation of host antitumor immunity. At present, four OV drugs have been approved for the treatment of cancers worldwide, two of which are oHSV drugs that have received extensive attention, known as T-VEC and Delytact. This review discusses the history, mechanism of action, clinical development, quality control, and evaluation principles of oHSV products, including viral species and genetic modifications that have improved these products’ therapeutic potential, limitations, and future directions. Integration of oHSVs with immunotherapeutic agents and conventional therapies has a promising future in the field of treatment of malignant tumors. Although much progress has been achieved, there is still much work to be done regarding the optimization of treatment protocols and the quality control of oncolytic virus drugs. The approval of various oncolytic virus therapies underlines their clinical relevance, safety, and efficacy, thereby paving the way for further research aimed at overcoming the existing limitations and enhancing patient responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirusesOncolytic VirotherapySimplexvirusNeoplasmsDrug DevelopmentHumansAnimalsQuality Control

Stichwörter der Autor:innen

combination therapydrug designevaluation principlesherpes simplex virusoncolytic virusquality control

Autor:innen und Institutionen

  • Shenzhen Key Laboratory of Viral Vectors for Biomedicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
  • NMPA Key Laboratory for Research and Evaluation of Viral Vector Technology in Cell and Gene Therapy Medicinal Products, CAS Key Laboratory of Brain Connectome and Manipulation, The Brain Cognition and Brain Disease Inst…
  • Key Laboratory of Quality Control Technology for Virus-Based Therapeutics, Guangdong Provincial Medical Products Administration, Guangdong Provincial Key Laboratory of Viral Biotechnology and Application, Shenzhen Insti…
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Department of Anesthesiology, Second Affiliated Hospital, Third Military Medical University, Chongqing 400037, China.
  • Shenzhen Institute for Drug Control, Shenzhen 518057, China.

ORCID-Profile: Tongtan Liu, Huadong Wang

Förderung

  • National Key Research and Development Program of China
  • Shenzhen Science and Technology Program
  • National Science and Technology Innovation 2030
  • Guangdong Basic and Applied Basic Research Foundation
  • Shenzhen Key Laboratory of Viral Vectors for Biomedicine
  • Key Laboratory of Quality Control Technology for Virus-Based Therapeutics, Guangdong Provincial Medical Products Administration
  • Science, Technology and Innovation Commission of Shenzhen
  • Guangdong Provincial Key Laboratory of Viral Biotechnology and Application

Zitieren

APA

Ghorab, B. E. A., Liu, T., Ying, M., Wang, P., Qin, M., Xing, J., Wang, H., & Xu, F. (2025). Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus. Viruses. https://doi.org/10.3390/v17040581

Vancouver

Ghorab BEA, Liu T, Ying M, Wang P, Qin M, Xing J, et al. Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus. Viruses. 2025. doi:10.3390/v17040581

BibTeX
@article{Ghorab2025,
  author = {Ghorab, Basma Eid Abdullah and Liu, Tongtan and Ying, Min and Wang, Ping and Qin, Meirong and Xing, Jiayong and Wang, Huadong and Xu, Fuqiang},
  title = {Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17040581}
}
Kostenlos starten →